Kyriakos Neofytou1, Alexandros Giakoustidis2,3, Mafalda Costa Neves1,4, Dawn Morrison4, Dimitris Giakoustidis5, Aamir Z Khan1, Justin Stebbing6, Satvinder Mudan1,4,7. 1. Department of Academic Surgery, Royal Marsden Hospital, Fulham Road, London, UK. 2. Department of Academic Surgery, Royal Marsden Hospital, Fulham Road, London, UK. alexgiakoustidis@gmail.com. 3. The London Clinic, 20 Devonshire Place, London, UK. alexgiakoustidis@gmail.com. 4. The London Clinic, 20 Devonshire Place, London, UK. 5. Department of Surgery and Transplantation, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 6. Department of Oncology, Imperial College Healthcare National Health Service Trust, Charring Cross Hospital, Fulham Palace Rd, London, UK. 7. Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
Abstract
BACKGROUND: The importance of preoperative chemotherapy in a multimodality management of patients with colorectal liver metastases (CRLM) has been demonstrated. We analyse the carcinoembryonic antigen (CEA) changes following neoadjuvant chemotherapy in patients with CRLM who underwent liver resection. METHODS: The final cohort included 107 eligible patients. Increased CEA levels following neoadjuvant chemotherapy were defined as the increase of baseline CEA level at diagnosis of CRLM compared with the CEA level after completion of neoadjuvant chemotherapy. Disease-free survival (DFS), post-recurrence survival (PRS) and overall survival (OS) were calculated using both Kaplan-Meier and multivariate Cox-regression methods. RESULTS: CEA increase was associated with decreased PRS and OS (HR 2.69; 95 % CI, 1.28-5.63; p = 0.009, and HR 2.50; 95 % CI, 1.12-5.56; p = 0.025, respectively) in multivariate analysis, but there was no association between CEA changes and DFS. CEA increase was only associated with disease progression during preoperative chemotherapy (p = 0.014). Interestingly, this association was not absolute, as only 5 of the 11 patients with disease progression demonstrated CEA increase. Regarding the remaining 12 patients with CEA increase, according to RECIST criteria, eight patients demonstrated partial response and four patients stable disease. CONCLUSION: In this study, we demonstrated the CEA increase following neoadjuvant chemotherapy as an adverse prognostic factor for PRS, and OS but not for DFS in patients undergoing liver resection for liver-only colorectal metastases.
BACKGROUND: The importance of preoperative chemotherapy in a multimodality management of patients with colorectal liver metastases (CRLM) has been demonstrated. We analyse the carcinoembryonic antigen (CEA) changes following neoadjuvant chemotherapy in patients with CRLM who underwent liver resection. METHODS: The final cohort included 107 eligible patients. Increased CEA levels following neoadjuvant chemotherapy were defined as the increase of baseline CEA level at diagnosis of CRLM compared with the CEA level after completion of neoadjuvant chemotherapy. Disease-free survival (DFS), post-recurrence survival (PRS) and overall survival (OS) were calculated using both Kaplan-Meier and multivariate Cox-regression methods. RESULTS: CEA increase was associated with decreased PRS and OS (HR 2.69; 95 % CI, 1.28-5.63; p = 0.009, and HR 2.50; 95 % CI, 1.12-5.56; p = 0.025, respectively) in multivariate analysis, but there was no association between CEA changes and DFS. CEA increase was only associated with disease progression during preoperative chemotherapy (p = 0.014). Interestingly, this association was not absolute, as only 5 of the 11 patients with disease progression demonstrated CEA increase. Regarding the remaining 12 patients with CEA increase, according to RECIST criteria, eight patients demonstrated partial response and four patients stable disease. CONCLUSION: In this study, we demonstrated the CEA increase following neoadjuvant chemotherapy as an adverse prognostic factor for PRS, and OS but not for DFS in patients undergoing liver resection for liver-only colorectal metastases.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Kyriakos Neofytou; Elizabeth C Smyth; Alexandros Giakoustidis; Aamir Z Khan; David Cunningham; Satvinder Mudan Journal: Med Oncol Date: 2014-09-14 Impact factor: 3.064
Authors: Raphael L C Araujo; Mithat Gönen; Peter Allen; Ronald DeMatteo; Peter Kingham; William Jarnagin; Michael D'Angelica; Yuman Fong Journal: Ann Surg Oncol Date: 2015-01-13 Impact factor: 5.344
Authors: Chan Wook Kim; Chang Sik Yu; Song-Soo Yang; Kyung Ho Kim; Yong Sik Yoon; Sang Nam Yoon; Seok-Byung Lim; Jin Cheon Kim Journal: Ann Surg Oncol Date: 2011-05-03 Impact factor: 5.344
Authors: Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; Felice Giuliante; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston Journal: Eur J Cancer Date: 2007-09-04 Impact factor: 9.162
Authors: James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544